Inovio Pharmaceuticals (NASDAQ:INO) released its quarterly earnings results on Wednesday. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.06, RTT News reports. Inovio Pharmaceuticals had a negative return on equity of 72.19% and a negative net margin of 221.55%. The firm had revenue of $8.80 million during the quarter, compared to the consensus estimate of $9.13 million. During the same quarter in the prior year, the firm posted ($0.35) EPS. The business’s revenue was up 3.5% on a year-over-year basis.
Shares of Inovio Pharmaceuticals (INO) traded down $0.07 during trading on Wednesday, hitting $4.47. The stock had a trading volume of 973,912 shares, compared to its average volume of 1,352,314. Inovio Pharmaceuticals has a one year low of $3.76 and a one year high of $9.86. The company has a market cap of $403.62, a PE ratio of -3.79 and a beta of 2.55.
A number of research firms have weighed in on INO. BidaskClub raised Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday. Maxim Group reduced their price target on Inovio Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating for the company in a research report on Thursday, February 15th. HC Wainwright set a $13.00 price target on Inovio Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, January 23rd. ValuEngine raised Inovio Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Wednesday, January 24th. Finally, Zacks Investment Research raised Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, January 9th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and eight have given a buy rating to the stock. Inovio Pharmaceuticals currently has an average rating of “Buy” and an average target price of $18.80.
WARNING: This piece was first reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.thelincolnianonline.com/2018/03/14/inovio-pharmaceuticals-ino-announces-earnings-results.html.
About Inovio Pharmaceuticals
Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.
Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.